Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074987 | 0.94 | — | — | |
| SCHEMBL607241 | 0.76 | — | — | |
| SCHEMBL2099498 | 0.72 | CYP1A2 (0.34) | — | |
| SCHEMBL4290268 | 0.72 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL8023826 | 0.71 | — | — | |
| SCHEMBL3485596 | 0.71 | — | — | |
| SCHEMBL3317288 | 0.71 | — | — | |
| SCHEMBL6506199 | 0.71 | L3MBTL1 (0.33) | — | |
| SCHEMBL2100033 | 0.71 | GRM2 (0.31) | — | |
| SCHEMBL1168662 | 0.71 | LTA4H (0.35) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190071399-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SYGNATURE DISCOVERY LTD (GB) | 2019-03-07 | — | — | US | claimed |
| EP-3426649-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Respivert Limited (GB) | 2019-01-16 | — | — | EP | claimed |
| WO-2017153748-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2017-09-14 | — | — | WO | claimed |
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | claimed |
| EP-2523957-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2012-11-21 | — | — | EP | claimed |
| CN-102712640-A | Tricyclic heterocyclic compounds, compositions and methods of use thereof | HOFFMANN LA ROCHE | 2012-10-03 | — | — | CN | claimed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | claimed |
| WO-2011086053-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | claimed |
| US-11208381-B2 | Indole derivatives and their use as protein kinase inhibitors | RESPIVERT LIMITED (GB) | 2021-12-28 | — | — | US | disclosed |
| US-20210114982-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2021-04-22 | — | — | US | disclosed |
| US-10669235-B2 | Indole derivatives and their use as protein kinase inhibitors | RESPIVERT LIMITED (GB) | 2020-06-02 | — | — | US | disclosed |
| US-20190071399-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | SYGNATURE DISCOVERY LTD (GB) | 2019-03-07 | — | — | US | disclosed |
| EP-3426649-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | Respivert Limited (GB) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017153748-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2017-09-14 | — | — | WO | disclosed |
| WO-2011086053-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | SERENEX, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| CN-1245402-C | indole derivatives, process for their preparation, pharmaceutical compositions containing them and their use | ASTRAZENECA AB (SE) | 2006-03-15 | — | — | CN | disclosed |
| US-20050033052-A1 | Novel compounds | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-02-10 | — | — | US | disclosed |
| CN-1468230-A | Compound (I) | — | 2004-01-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050033052-A1 | Novel compounds | LTA4H, PLA2G1B, PLA2G4B | ALDH1A1 775/4885KDM4E 3137/4885NPSR1 2214/4885 |
| US-10669235-B2 | Indole derivatives and their use as protein kinase inhibitors | GRK3, IDO1, CIT | ALDH1A1 2888/4885KDM4E 1071/4885NPSR1 1432/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | ALDH1A1 4094/4885KDM4E 2238/4885NPSR1 675/4885 |
| US-11208381-B2 | Indole derivatives and their use as protein kinase inhibitors | GRK3, IDO1, CIT | ALDH1A1 2888/4885KDM4E 1071/4885NPSR1 1432/4885 |
| US-20190071399-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | GRK3, IDO1, CIT | ALDH1A1 2888/4885KDM4E 1071/4885NPSR1 1432/4885 |
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | HSF1, HSP90AB1, TPH1 | ALDH1A1 479/4885KDM4E 3880/4885NPSR1 1489/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | ALDH1A1 1168/4885KDM4E 2333/4885NPSR1 2720/4885 |
| US-20210114982-A1 | INDOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | GRK3, IDO1, CIT | ALDH1A1 2888/4885KDM4E 1071/4885NPSR1 1432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.